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Abstract
Background: Treatment possibilities of metastatic renal cell carcinoma (mRCC) have recently changed dramatically
prolonging the overall survival of the patients. This kind of development brings new challenges for the care of mRCC.
Case presentation: A 22 year-old female patient with translocation type mRCC, who previously had been treated for
nearly 5 years, became pregnant during the treatment break period. Follow-up examinations revealed a dramatic
clinical and radiological progression of mRCC in a few weeks therefore the pregnancy was terminated. A few days after
surgical abortion, CT examination showed a significant spontaneous regression of the pulmonary metastases, and the
volume of the largest manifestation decreased from ca. 30 to 3.5 cm3 in a week. To understand the possible mechanism
of this spectacular regression, estrogen, progesterone and luteinizing hormone receptors (ER, PGR and LHR, respectively)
immuno-histochemistry assays were performed on the original surgery samples. Immuno-histochemistry showed
negative ER, PGR and positive LHR status suggesting the possible angiogenic effect of human chorionic gonadotropin
hormone (hCG) in the background.
Conclusion: We hypothesize that pregnancy may play a causal role in the progression of mRCC via the excess amount
of hCG, however, more data are necessary to validate the present notions and the predictive role of LHR overexpression.
Keywords: Human chorionic gonadotropin hormone, Luteinizing hormone receptor, Metastasis, Pregnancy, Renal cell
carcinoma
Background
Treatment possibilities of metastatic renal cell carcinoma
(mRCC) have changed dramatically in the last decade from
conventional cytokine-based chemo-immunotherapies to
therapies using broad spectra of targeted drugs and, most
recently, immune system modulator agents [1–3]. These
new treatment modalities have increased the median over-
all survival of mRCC beyond two years, naturally poor,
moderate and good risk patients still have different clinical
outcomes [1–4]. As a consequence of this kind of develop-
ment and the increasing number of fertile female patients
surviving for a long time it has become more important to
get acquainted with the possible interaction of the progres-
sion of mRCC with pregnancy and child-bearing potential.
Both treatment possibilities and the outcome of cancer
diseases during pregnancy are well discussed in the med-
ical literature [5–14]. Numerous publications report suc-
cessful pregnancies and deliveries in the case of breast
cancer, gynecological tumors and hematological malig-
nancies, with the respect of the oncologic point of view.
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In some tumor entities (e.g., breast cancer over the first
trimester, early kidney tumors, etc.) the treatment recom-
mendations are similar to those for non-pregnant women,
in other cases the treatment decisions have to be consid-
ered under critical evaluation [5–14]. Several case reports
and reviews are also available concerning the challenges
associated with kidney cancers diagnosed in pregnant
women [15–22]. However, there is only limited knowledge
about the behavior of metastatic renal cell carcinoma dur-
ing pregnancy so far [23, 24].
Here we review the case of a very young female patient
with disseminated kidney cancer who became pregnant
after her initial anticancer treatment. Her disease pro-
gressed quickly therefore surgical abortion had to be car-
ried out. Following the abortion an amazing clinical and
radiological improvement was observed without any fur-
ther therapeutic intervention. The rate and extent of the
tumor regression was more outstanding than it could
have been expected due to any kind of effective antican-
cer treatment.
Case presentation
The primary check up of a 16-year-old, twin-born female
Caucasian patient with no relevant medical history started
due to both weight loss and a mass which was found in the
right kidney. Nephrectomy was carried out in January 2007.
Macroscopically a 14 cm large, solid and cystic tumor mass
was seen with focal necroses and haemorrhages (pT2 pN0).
Histology showed a juvenile Xp 11.2 translocation type
renal cell carcinoma (Fig. 1). The tumor cells were arranged
in papillary or trabecular-alveolar structures. They had
large, clear to light pink cytoplasm and small nucleoli. Just
a few mitoses were seen and no vascular invasion was
detected. The immuno-histochemical (IHC) analysis proved
focal EMA, CK (AE1-3) and CD10 reactions. The TFE-3
staining showed intense nuclear reaction.
The patient was only observed till August 2007, when
an intraperitoneal relapse was confirmed. Following
metastasectomy chemo-immunotherapy was initiated
with the combination of recombinant interferon alfa 2a
and vinblastine. In February 2008 sunitinib therapy was
introduced due to local, peritoneal and pulmonary pro-
gression. Continuous regression was observed until
March 2009, when mediastinal-hilar relapse was re-
vealed. The dose of sunitinib was increased from a
daily 50 mg to a daily 62.5 mg dosage achieving further
tumor response without any serious adverse events. In
August 2009 cerebral progression was confirmed. Then
the sunitinib treatment was terminated. After surgical
removal of the biggest occipital metastasis, whole brain
radiotherapy (RT) was initiated. Having delivered only
limited RT dose (4 Gy in 2 fractions), a second neuro-
surgery had to be carried out due to tumor progression
and mass effect. A second-line sorafenib treatment was
started in October 2009 and four months later the re-
sidual cerebral mass was removed with a third neuro-
surgical intervention. Up to January 2011 all control
examinations showed good tumor regression under
continuous sorafenib medication with tolerable (Grade
1–2) side effects. During the year of 2011 due to medi-
astinal and suprarenal progression sorafenib medication
was terminated and without having any effective fourth
line systemic treatment first mediastinal irradiation was
carried out. This was followed by surgical removal of
the suprarenal manifestation. Thus, after achieving ex-
cellent tumor control without any systemic therapy, our
oncology team recommended the watch and wait ap-
proach, and further observation was carried out from
the spring of 2012.
In August 2012, when the patient was 22 years old, a 13-
week-old pregnancy was verified by gynecological examin-
ation. During her anticancer treatment she was informed
about the importance of using contraception and she re-
portedly used only physical contraceptive methods. The
patient insisted on her pregnancy, although she was fully
informed of the risk of her decision. At the end of August
the first chest X-ray examination recorded two new pul-
monary manifestations, with diameters of 29 × 19 mm and
18 × 11 mm. Twelve days later chest MRI was carried
out, showing rapid progression of the lung metastases
with largest diameters of 41, 16 and 11 mm, and with
bilateral hilar and right supraclavicular lymph node
manifestations. Due to the significant progression and
the appearance of clinical symptoms our patient chan-
ged her decision and accepted the surgical abortion of
her pregnancy. During this period the respiratory dis-
tress deteriorated. Following the abortion, the patient’s
complaints ceased and the size of the neck mass de-
creased. Chest X-ray examination showed regression
compared to the previous X-ray findings (Fig. 2).
Fig. 1 Xp 11.2 translocation carcinoma, with TFE3 fusion
protein immunostaining
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The patient received ergotamine and bromocriptine
medication immediately after the abortion. Eight days
after the abortion chest CT examination was carried out
to verify the tumor regression. Results revealed rapid re-
gression of the pulmonary manifestations (Fig. 3): the
diameter of the largest metastasis decreased to 23 mm
and the volume decreased from 30.02 cm3 to 3.51 cm3
based on the measurements of two independent ob-
servers. Without any anticancer treatment, within one
week the tumor shrinkage rate was at least 85–90 %,
compared to the pre-abortion volume. Meanwhile the
diameter of the palpable supraclavicular mass decreased
as well, from about 3 cm to 2 cm.
In the beginning of November 2012 the check-up CT
showed a stable disease without any therapeutic interven-
tion. One month later the chest X-ray revealed progression
in one of pulmonary manifestations, therefore interferon
re-induction was initiated based on the hypothetical post-
abortion immunological effect and the patient’s preference.
In January 2013 restaging CT examinations demonstrated
multi-organ progression therefore the interferon medica-
tion was terminated. The patient received RT, followed by
the fourth neurosurgical intervention in order to remove a
frontal cerebral metastasis, which caused mass effect.
Completing whole brain RT (36 Gy in 18 fractions) suniti-
nib re-challenge treatment strategy was introduced in a
continuous daily dosing of 25 mg. The next brain MRI
showed regression of the residual cerebral lesions however,
the whole-body CT revealed unambiguous and rapid
abdominal (liver and adrenal gland) and multiple bone
progression. The general condition of the patient deterio-
rated, so we delivered palliative irradiation to the painful
vertebral bones (20 Gy in 5 fractions) and medroxy-
progesterone medication was initiated. Due to the rapid
progression and multi-organ failure, 6 years after the first
diagnosis, at the end of June 2013 we lost our patient.
To prove the potential role of hormonal effects during
pregnancy IHC examinations were performed on the ori-
ginal biopsy and surgery samples of the primary tumor
and the metastases. The presence and density of Estrogen,
Progesterone and Luteinizing Hormone Receptors (ER,
PGR and LHR, respectively) were analyzed. ER (SP1,
rabbit monoclonal, 1:50, Histopathology Ltd.) and PGR
(SP2, rabbit monoclonal, 1:100, Histopathology Ltd.) pri-
mary antibodies were used (both with Bond Epitope
Retrieval solution) and Bond Polymer Refine Detection
(Leica, Germany) was applied as a developer system on
Bond TM. LHR antibody (H-50: sc-25828, rabbit poly-
clonal IgG, Santa Cruz Biotechnology, Dallas, Texas) was
used as primary antibody at 2ug/ml final concentration
with citrate buffered heat retrieval, pH6. Deparaffinized
sections were pretreated with EnVisionTM FLEX Target
Fig. 2 Chest X-ray examination before (left) and after (right) surgical abortion. The diameter of the largest pulmonary manifestation decreased significantly
Fig. 3 Chest MRI and CT examination before (left) and after (right) surgical abortion. The volume of the largest pulmonary manifestation decreased from
30.02 cm3 to 3.51 cm3
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Retrieval Solution, 3 in 1, Low pH (20′) - K8005. The reac-
tion was developed on Dako Autostainer (Dako, Denmark)
with EnVisionTM FLEX, High pH, HRP, Rb/Mo - K800021
according to the vendors’ guideline.
IHC staining revealed no ER (Fig. 4) or PGR activity.
However, a high density of LHR-s was unambiguously de-
tected (Fig. 5), indirectly proving the potential mitogenic
effect of human chorionic gonadotropin hormone (hCG).
Case discussion
Renal cell carcinoma is generally characterized by im-
munogenic properties and slow progression. The volume
doubling time of primary RCC is considered to be about
72 weeks [16]. The progression of mRCC is also gener-
ally slow, especially in the elderly [25]. There are several
case reports about rapidly growing kidney tumor during
pregnancy. For example, Bettez et al. [16] reported a
fatal fast growing RCC during pregnancy, the diameter
of the renal mass increased from 34 mm to 93 mm in
15 weeks. In the present study a similar growth rate was
observed in a few weeks time.
Spontaneous regression of mRCC after surgical inter-
vention or even without nephrectomy is a well-known
phenomenon [26]. Sometimes it can be observed in a very
fast manner. Otherwise, in the age of targeted therapies, a
moderate regression can be realized in the routine clinical
practice. We have limited data concerning the speed of
the tumor shrinking effect. In the volumetric analyses by
Stein the typical shrinkage rate was moderate as well. In
case of successful treatments the largest diameter of the
tumors came to be halved in 1 to 3 months [27]. In our
case a similar shrinkage rate was observed within 8 days.
In the routine clinical practice similar rapid tumor reac-
tions can only be observed during the treatment of lymph-
omas and neuroendocrine small cell carcinomas.
The mechanism of the presently observed enormous
tumor shrinkage is not known and may not be expected,
moreover, the possible effect of post-abortion medication
also cannot be excluded. Nevertheless, several endocrine,
immunologic and vascular factors could also play a role in
the background. It is widely accepted that some renal can-
cers express ER and PGR [28]. The dramatic decrease in
the serum level of sex hormones due to the surgical abor-
tion could result in an anti-estrogen effect and inhibition
of cell division. However we did not succeed in proving
any hormonal sensitivity of the present tumor.
Metastatic RCC is considered to be a highly immuno-
genic tumor. Pregnancy can alter the immune reactions
and auto-immunity in case of chronic lymphoid leukemias
[11]. Pregnancy is a special immunological state; the hor-
monal imbalance is important in order to maintain gravid-
ity and the placenta produces several cytokines, tumor
necrosis factors, growth and angiogenic factors. Natural
killer cells, monocytes can be observed in the decidual
tissues thereby influencing the behavior of the malignan-
cies [29, 30]. With the removal of the placenta an inverse
immune reaction can be supposed which may inhibit the
further growth of the tumor. Nevertheless, in the present
study, no significant inflammation or leukocyte, lympho-
cyte infiltration was noticed in the original tissue sample.
However, none of the above hypotheses can elucidate the
observed rapid tumor regression, the spectacular necrosis
or apoptosis of the cancer cells and the fast elimination of
the destroyed tissues.
The angiogenic factors play a key role in the develop-
ment of renal cell carcinoma. The clinical application of
several types of vascular endothelial growth factor (VEGF)
inhibitor agents (TKIs as sunitinib, sorafenib, pazopanib
or the VEGF ligand binding bevacizumab) dramatically
changed the treatment of mRCC [1–3]. The formation of
new vessels is an important factor in the development and
growth of the placenta as well [31]. Decidual fibroblasts
produce different vascular endothelial growth factors. It is
Fig. 4 Negative ER status on IHC examination of the tumor
Fig. 5 Extremely high density of LHR on IHC examination of
the tumor
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also important that the plasma placental growth factor
(PlGF) level with angiogenic potential is reportedly higher
in mRCC patients. Moreover, PlGF and VEGF level could
be associated with the clinical features of RCC [32]. The
results of in-vitro mRNA analyses suggest that VEGF,
PlGF, and basic fibroblast growth factor work coopera-
tively to increase the angiogenesis in RCC [33]. Another
vascular way could be the rapid change in the level of
endocrine gland-derived vascular endothelial growth
factor (EG-VEGF). EG-VEGF is an angiogenic factor re-
ported to be specific for the placenta and potentially
regulated by hCG [34].
Human chorionic gonadotropin hormone, which is equal
to a group of 5 molecules having separate biological func-
tions and often called the “everything molecule”, plays an
important role in maintaining decidual functions and preg-
nancy via angiogenic effect ensuring the growth of the
foetus [35]. The role that hCG may play in the oncogenic
process of cancer is certainly complex. Nevertheless, it is
suspected that hCG is involved in the angiogenesis, in the
development of metastasis and the immune escape central
to cancer progression. Human chorionic gonadotropin hor-
mone variants antagonize the TGFß receptor, promoting
cell growth and blocking cell apoptosis [35–37]. Based on
X-ray crystallographic structure studies hCG is considered
to be a member of the “cystine knot growth factor/TGFβ
(CKGF) oncoprotein superfamily” (TGFβ, PDGFB, VEGF,
PlGF, hCG etc.), supposing the cross-talk between the
multiple growth regulatory systems [35–37]. HCG stimu-
lates angiogenesis through TGFβ receptor activation, and
hCG- TGFβ receptor plays a key role in the angiogenesis
associated both with the placental development and the
tumorigenesis [38].
It is known that the expression of hCG and its beta sub-
unit is a widespread phenomenon that has been described
in many cancer subtypes. The cluster of choriogonadotro-
pin sensitive tumors, such as choriocarcinoma and testicu-
lar cancers is well known [36]. The incidence of hCG
expression varies in different epithelial tumor types, posi-
tive detection ranges from 0 % in RCC to 93 % in small
cell lung cancer with an average of 30 % by IHC [37].
Many authors noted the aggressive nature of hCG positive
tumors. Moreover hCG expression is more likely to be the
result of altered gene regulation and it is regarded as a
marker of the presence of pluripotent stem/germ cells
[35–37]. In the last decade, several clinical studies tried to
prove the therapeutic effect of anti-hCGβ cancer vaccine
[35–37]. However, hCG can play a preventive role in
breast cancer [37].
As mentioned before in the work of Berzal-Cantaleyo
RCC samples showed no hCG positivity by IHC [35].
However, reverse transcription-polymerase chain reaction
(RT-PCR) and restriction endonuclease analyses show that
52 % RCC tissue samples proved to be positive for beta
hCG mRNA expression [39]. Hotakainen et al. found an
increased level of beta subunit in 23–40 % of RCC pa-
tients, concluding the negative prognostic value of hCG
positivity in their work [40, 41]. Translocation type RCC is
generally considered to be a rapidly growing tumor [15].
The aggressive clinical behavior of the tumor in our case
is attached to an increased hCG expression, as well. Sev-
eral other case reports describe hCG producing RCC [42].
The hCG receptor is generally considered to be practic-
ally equivalent to luteinizing hormone receptor (LHR) and
the examination of LHR overexpression is well accepted
in the literature [35, 36]. The role of LHR expression and
activation is uncertain in cancer progression, even if it
prevents cancer cell proliferation [43]. LHR expression is
common in different cancer types, including RCC as well
[44]. We analyzed the density of LHR in the original tissue
blocks of the patient by IHC and succeeded in proving the
potential role of hCG in the course of the disease.
These findings support the theory about the role of
placental angiogenic factors and hCG in the growth of a
tumor during pregnancy and in the regression after sur-
gical abortion. The enormous shift in vascular activity
after abortion could explain the rapid decrease of the
tumor mass. Presumably, the rapid decrease in the PlGF
and hCG plasma levels may have negative effects on the
VEGF plasma levels, as well. The fast tumor shrinkage
in such a highly vascularized tumor type as RCC may be
explained with the facts above.
Conclusions
Our case study proved that pregnancy may promote
the progression of mRCC. The excess production of
hCG which is normally important to maintain gravidity
could play a special role in the progression-regression
phenomenon of mRCC. However, more new clinical
data are necessary to validate the present notions about
the general predictive role of LHR overexpression in
fast growing cancers during pregnancy. Nevertheless,
there is a further need to investigate the effects of an-
giogenic, growth and endocrine factors. Doing so will
help better understand the biological behavior of differ-
ent RCC types and cancer during pregnancy.
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